JP2022534837A5 - - Google Patents

Info

Publication number
JP2022534837A5
JP2022534837A5 JP2021558535A JP2021558535A JP2022534837A5 JP 2022534837 A5 JP2022534837 A5 JP 2022534837A5 JP 2021558535 A JP2021558535 A JP 2021558535A JP 2021558535 A JP2021558535 A JP 2021558535A JP 2022534837 A5 JP2022534837 A5 JP 2022534837A5
Authority
JP
Japan
Prior art keywords
cancer
chimeric protein
cells
disease
protein complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021558535A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022534837A (ja
JP7689079B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/025411 external-priority patent/WO2020198654A1/en
Publication of JP2022534837A publication Critical patent/JP2022534837A/ja
Publication of JP2022534837A5 publication Critical patent/JP2022534837A5/ja
Priority to JP2025019797A priority Critical patent/JP2025072580A/ja
Application granted granted Critical
Publication of JP7689079B2 publication Critical patent/JP7689079B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021558535A 2019-03-28 2020-03-27 治療用インターフェロンアルファ1タンパク質 Active JP7689079B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025019797A JP2025072580A (ja) 2019-03-28 2025-02-10 治療用インターフェロンアルファ1タンパク質

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962825569P 2019-03-28 2019-03-28
US62/825,569 2019-03-28
US201962906431P 2019-09-26 2019-09-26
US62/906,431 2019-09-26
PCT/US2020/025411 WO2020198654A1 (en) 2019-03-28 2020-03-27 Therapeutic interferon alpha 1 proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025019797A Division JP2025072580A (ja) 2019-03-28 2025-02-10 治療用インターフェロンアルファ1タンパク質

Publications (3)

Publication Number Publication Date
JP2022534837A JP2022534837A (ja) 2022-08-04
JP2022534837A5 true JP2022534837A5 (cg-RX-API-DMAC7.html) 2023-04-03
JP7689079B2 JP7689079B2 (ja) 2025-06-05

Family

ID=72603959

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021558535A Active JP7689079B2 (ja) 2019-03-28 2020-03-27 治療用インターフェロンアルファ1タンパク質
JP2025019797A Pending JP2025072580A (ja) 2019-03-28 2025-02-10 治療用インターフェロンアルファ1タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025019797A Pending JP2025072580A (ja) 2019-03-28 2025-02-10 治療用インターフェロンアルファ1タンパク質

Country Status (6)

Country Link
US (2) US11440943B2 (cg-RX-API-DMAC7.html)
EP (1) EP3946410A4 (cg-RX-API-DMAC7.html)
JP (2) JP7689079B2 (cg-RX-API-DMAC7.html)
CN (1) CN113767115B (cg-RX-API-DMAC7.html)
CA (1) CA3133643A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020198654A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3455245A2 (en) * 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutic targeting of non-cellular structures
WO2020198665A1 (en) 2019-03-28 2020-10-01 Orionis Biosciences, Inc. Fibroblast activation protein binding agents and use thereof
JP7689079B2 (ja) * 2019-03-28 2025-06-05 オリオニス バイオサイエンシズ,インコーポレイテッド 治療用インターフェロンアルファ1タンパク質
CN114761430A (zh) * 2019-09-26 2022-07-15 奥里尼斯生物科学股份有限公司 靶向pd-l1的嵌合蛋白及其用途
CA3163358A1 (en) 2019-12-03 2021-06-10 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
CN113717942B (zh) * 2020-05-26 2024-04-30 华东师范大学 一种联合嵌合抗原受体和i型干扰素的免疫治疗方法及其应用
WO2022140797A1 (en) * 2020-12-23 2022-06-30 Immunowake Inc. Immunocytokines and uses thereof
EP4281107A4 (en) * 2021-01-22 2025-03-12 Celldex Therapeutics, Inc. ANTI-KIT ANTIBODIES AND USES THEREOF
WO2023016564A1 (zh) * 2021-08-12 2023-02-16 上海才致药成生物科技有限公司 靶向GPC3的抗体干扰素α融合蛋白及其用途
CA3232777A1 (en) * 2021-08-18 2023-02-23 Remd Biotherapeutics, Inc. Novel interferon variants and bifunctional fusion molecules thereof
EP4543488A2 (en) * 2022-08-25 2025-04-30 Bright Biologics LLC Multispecific antibodies and uses thereof
WO2026076281A1 (en) * 2024-10-04 2026-04-09 Orionis Biosciences, Inc. Interleukin-6 agonist chimeric proteins
WO2026104336A1 (en) 2024-11-13 2026-05-21 F. Hoffmann-La Roche Ag Immunoconjugates

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
EP0489116B1 (en) 1989-08-22 1994-04-06 Immunex Corporation Fusion proteins comprising gm-csf and il-3
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
SI1121382T1 (sl) 1998-10-16 2007-02-28 Biogen Idec Inc Fuzijski proteini interferona-beta in uporabe
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
US20020193569A1 (en) 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
US20110020273A1 (en) * 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
WO2006004959A2 (en) * 2004-06-30 2006-01-12 Egen Corporation Pegylated interferon alpha-1b
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
WO2006115800A2 (en) 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
US20060251619A1 (en) 2005-05-04 2006-11-09 Gilles Borrelly Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
US20080038224A1 (en) 2006-03-28 2008-02-14 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
US7947265B2 (en) 2006-08-02 2011-05-24 Mcgill University Fusion proteins and methods for modulation of immune response
US8907065B2 (en) 2006-12-15 2014-12-09 Ablynx N.V. Polypeptides that modulate the interaction between cells of the immune system
WO2008124086A2 (en) 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
WO2009003145A1 (en) 2007-06-26 2008-12-31 University Of Miami Antibody-endostatin fusion protein and its variants
ES2536772T3 (es) 2007-09-21 2015-05-28 The Regents Of The University Of California El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
CN101525381B (zh) 2008-03-04 2012-04-18 北京百川飞虹生物科技有限公司 一种重组复合干扰素及其表达载体的构建和表达
WO2010030671A1 (en) 2008-09-09 2010-03-18 University Of Medicine And Dentistry Of New Jersey Type i interferon antagonists
US8334101B2 (en) 2008-09-26 2012-12-18 University Of Massachusetts Intracellular DNA receptor
CA2749558C (en) 2008-12-08 2019-01-15 Complix Nv Single-chain antiparallel coiled coil proteins
WO2011017160A1 (en) * 2009-07-28 2011-02-10 Pestka Biomedical Laboratories, Inc. Mutant human interferon proteins and genes
RU2583876C2 (ru) 2009-08-17 2016-05-10 Роше Гликарт Аг Иммуноконъюгаты направленного действия
CN102497885A (zh) 2009-09-10 2012-06-13 赛托斯生物技术公司 白介素-1β突变蛋白偶联物在糖尿病治疗中的用途
EP2343081A1 (en) 2009-12-31 2011-07-13 Rijksuniversiteit Groningen Interferon analogs
WO2012170072A1 (en) 2011-06-06 2012-12-13 Immungene, Inc. Engineered antibody-tnfsf member ligand fusion molecules
CN104203982B (zh) 2011-10-28 2018-08-31 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
WO2013107791A1 (en) 2012-01-20 2013-07-25 Vib Vzw Targeted mutant alpha-helical bundle cytokines
PL2822575T3 (pl) 2012-03-03 2020-08-10 Immungene, Inc. Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu
CN111363047A (zh) 2013-03-12 2020-07-03 分子模板公司 用于引起细胞内化的cd20结合免疫毒素及其使用方法
CN103319608B (zh) * 2013-07-01 2014-08-27 江苏众红生物工程创药研究院有限公司 猪IFNɑ1-Fc融合蛋白及其编码基因和表达方法
KR102322510B1 (ko) 2013-07-18 2021-11-08 브이아이비 브이지더블유 수용체 결합친화성이 현격히 감소된 사이토카인을 수반하는 푸소카인
MX370565B (es) 2013-07-19 2019-12-17 Vib Vzw Miembros de la familia tnf modificados dirigidos.
CA2918518C (en) 2013-07-19 2022-08-16 Universiteit Gent Targeted modified il-1 family members
US9732135B2 (en) 2013-07-19 2017-08-15 Vib Vzw Targeting of human interferon antagonists
EP3371311B1 (en) 2015-11-06 2021-07-21 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
CN109071632B (zh) 2016-02-05 2022-12-30 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
US11248057B2 (en) 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies
WO2017158436A1 (en) 2016-03-17 2017-09-21 Oslo Universitetssykehus Hf Fusion proteins targeting tumour associated macrophages for treating cancer
EP3455245A2 (en) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutic targeting of non-cellular structures
WO2017194783A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
CN110114368B (zh) 2016-10-24 2024-08-02 奥睿尼斯生物科学私人有限公司 靶向突变干扰素-γ及其用途
EP3576765B1 (en) 2017-02-06 2025-07-16 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
CA3050601A1 (en) 2017-02-07 2018-08-16 Vib Vzm Immune-cell targeted bispecific chimeric proteins and uses thereof
CN117924493A (zh) 2017-08-09 2024-04-26 奥里尼斯生物科学有限公司 Clec9a结合剂及其用途
EP3664829A4 (en) 2017-08-09 2021-05-05 Orionis Biosciences, Inc. LIAISON OFFICERS AT PD-1 AND PD-L1
EP3665201A4 (en) 2017-08-09 2021-06-02 Orionis Biosciences, Inc. CD8 BINDERS
US12655186B2 (en) 2018-01-26 2026-06-16 Orionis Biosciences, Inc. Chimeric protein comprising anti-XCR1 antibody and modified interferon alpha 2
CA3090406A1 (en) 2018-02-05 2019-08-08 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
KR20260100427A (ko) 2018-03-28 2026-06-29 오리오니스 바이오사이언시즈 인코포레이티드 이작용성 단백질 및 이의 작제물
EP3833391A4 (en) * 2018-08-08 2022-08-10 Orionis Biosciences, Inc. ANTI-SIRP1ALPHA CHIMERIC PROTEINS AND USES THEREOF
EP3890773A4 (en) 2018-11-08 2022-11-09 Orionis Biosciences, Inc. MODULATION OF DENDRITIC CELL LINES
CA3125527A1 (en) 2018-12-20 2020-06-25 Orionis Biosciences, Inc. Particle based small molecule-protein complex trap
JP7689079B2 (ja) * 2019-03-28 2025-06-05 オリオニス バイオサイエンシズ,インコーポレイテッド 治療用インターフェロンアルファ1タンパク質
JP7729778B2 (ja) * 2019-03-28 2025-08-26 オリオニス バイオサイエンシズ,インコーポレイテッド Fms様チロシンキナーゼ3(flt3)に対するキメラタンパク質およびキメラタンパク質複合体

Similar Documents

Publication Publication Date Title
JP2024522949A5 (cg-RX-API-DMAC7.html)
Strohl Current progress in innovative engineered antibodies
JP5745854B2 (ja) Tl1aに対するヒト化抗体
JP2020506727A5 (cg-RX-API-DMAC7.html)
JP2020501531A5 (cg-RX-API-DMAC7.html)
US20200087377A1 (en) Multifunctional Fusion Protein and Applications Thereof
JP2022515318A5 (cg-RX-API-DMAC7.html)
TW202003583A (zh) 抗muc1抗體
JP2020531043A5 (cg-RX-API-DMAC7.html)
JP2021513361A5 (cg-RX-API-DMAC7.html)
RU2018139339A (ru) Новые биспецифические полипептиды против cd137
RS62151B1 (sr) Konstrukti koji sadrže sirp-alfa domen ili njegovu varijantu
US12312409B2 (en) Bispecific CD137-binding antibodies for T-cell activation
Han et al. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy
KR20160127131A (ko) 항 인간 인터루킨-1 수용체 부속 단백질 (il1 rap) 항체 및 이의 용도
CN104470536A (zh) 工程化的抗体-干扰素突变体融合分子
JP2022512891A5 (cg-RX-API-DMAC7.html)
US20230374157A1 (en) Specificy-enhanced bispecific antibody (seba)
JP2022550345A5 (cg-RX-API-DMAC7.html)
JP2025148434A (ja) PD-1とTGF-βに対する二機能性タンパク質
JP7812988B2 (ja) Lewis Yに対するヒト化抗体
JP2019512210A5 (cg-RX-API-DMAC7.html)
KR20250075712A (ko) B7h3/pdl1 이중특이성 항체 및 이의 약학 조성물과 응용
EP4667491A1 (en) Anti-cntn4 antibody and uses thereof
JP2024503657A5 (cg-RX-API-DMAC7.html)